- Gilead Sciences (NASDAQ:GILD) is holding steady after hours on the heels of its announcement that its Phase 3 clinical trial, STELLAR-4, evaluating selonsertib in NASH patients with compensated cirrohosis failed to sufficiently separate from placebo.
- The study failed to meet the primary endpoint of the proportion of participants achieving at least a one-stage improvement in NASH classification after 48 weeks of treatment. Specifically, 14.4% of patients receiving 18 mg of selonsertib and 12.5% of those receiving 6 mg achieved at least a one-stage improvement in NASH compared to 12.8% for placebo.
- On the plus side, selonsertib was generally safe and well-tolerated.
- Topline results from the Phase 3 STELLAR-3 study in NASH patients with bridging fibrosis and the Phase 2 ATLAS trial in NASH patients with advanced fibrosis should be available later this year.
- Now read: Gilead Doubles Down On Its NASH Pipeline With .5B Deal
Original article